Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes

被引：0
|
作者：
Wei, Andrew H. [1 ,2 ,3 ]
Seymour, John F. [1 ,2 ]
机构：
[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
基金：
英国医学研究理事会;
关键词：
myelodysplastic syndromes; Hypomethylating agents; lenalidomide; CONVENTIONAL CARE REGIMENS; AZACITIDINE; LENALIDOMIDE; CLASSIFICATION; COMBINATION;
D O I：
10.1111/bjh.18240
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hypomethylating agents remain the current standard of care for patients with higher-risk myelodysplastic syndromes. Ades et al. report outcomes from a randomised 'pick-a-winner' study design that examined the addition of either lenalidomide, valproic acid or idarubicin in combination with azacitidine, compared to azacitidine alone. Commentary on: Ades et al. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS: GFM's 'pick a winner' trial, with the impact of somatic mutations. Br J Haematol 2022 (Online ahead of print). doi: 10.1111/bjh.18193.
引用
下载
收藏
页码：415 / 418
页数：4
相关论文
共 50 条
  • [31] Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (01)
  • [32] In vitro preclinical assessment of alvocidib in combination with 5-azacytidine in higher-risk myelodysplastic syndromes
    Riabov, V
    Xu, Q.
    Schmitt, N.
    Streuer, A.
    Jann, J. -C
    Wein, A.
    Altrock, E.
    Mehralivand, A.
    Nowak, V
    Weimer, N.
    Oblaender, J.
    Palme, I
    Jawhar, A.
    Weiss, C.
    Metzgeroth, G.
    Foulks, J. M.
    Hofmann, W-K
    Nowak, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 99 - 99
  • [33] 5-azacytidine in the treatment of Greek patients with higher-risk myelodysplastic syndromes. An overview
    Zervakis, K.
    Diamantopoulos, P.
    Papadopoulou, V.
    Iliakis, T.
    Mpakarakos, P.
    Kalala, F.
    Giannakopoulou, N.
    Rougkala, N.
    Galanopoulos, A.
    Variami, E.
    Dimitrakopoulou, A.
    Viniou, N.
    LEUKEMIA RESEARCH, 2013, 37 : S159 - S159
  • [34] ACCURACY OF PHYSICIAN ASSESSMENT OF TREATMENT PREFERENCES AND HEALTH STATUS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Caocci, G.
    Voso, M. T.
    Angelucci, E.
    Stauder, R.
    Cottone, F.
    Abel, G.
    Nguyen, K. T. T.
    Platzbecker, U.
    Beyne-Rauzy, O.
    Gaidano, G.
    Invernizzi, R.
    Molica, S.
    Criscuolo, M.
    Breccia, M.
    Luebbert, M.
    Sanpaolo, G.
    Buccisano, F.
    Ricco, A.
    Palumbo, G.
    Niscola, P.
    Zhang, H.
    Fenu, S.
    La Nasa, G.
    Mandelli, F.
    Efficace, F.
    HAEMATOLOGICA, 2015, 100 : 23 - 23
  • [35] Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
    Razan Mohty
    Rama Al Hamed
    Ali Bazarbachi
    Eolia Brissot
    Arnon Nagler
    Amer Zeidan
    Mohamad Mohty
    Journal of Hematology & Oncology, 15
  • [36] Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
    Mohty, Razan
    Al Hamed, Rama
    Bazarbachi, Ali
    Brissot, Eolia
    Nagler, Arnon
    Zeidan, Amer
    Mohty, Mohamad
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [37] Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
    Bazinet, Alexandre
    Desikan, Sai Prasad
    Li, Ziyi
    Rodriguez-Sevilla, Juan Jose
    Venugopal, Sangeetha
    Urrutia, Samuel
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Chien, Kelly S.
    Hammond, Danielle
    Kanagal-Shamanna, Rashmi
    Ganan-Gomez, Irene
    Kadia, Tapan M.
    Borthakur, Gautam
    Dinardo, Courtney D.
    Daver, Naval G.
    Jabbour, Elias J.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1319 - 1326
  • [38] Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks
    Pollyea, Daniel A.
    Gutman, Jonathan A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (04) : 421 - 431
  • [39] Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks
    Daniel A. Pollyea
    Jonathan A. Gutman
    Current Hematologic Malignancy Reports, 2014, 9 : 421 - 431
  • [40] An Update on Higher Risk Myelodysplastic Syndromes
    Hochman, Michael J.
    DeZern, Amy E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S21 - S25
12345